Multiple platforms like cobas, BEAMing, ddPCR and NGS are capable of detecting EGFR TKI resistant mutations in NSCLC patients though they differ in their sensitivity, specificity and turnaround time. This evidence concerns the gene EGFR and non-small cell lung carcinoma.